| Issue Date |
Title |
Author(s) |
| 2017 |
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses |
Mok, Tony S. K.;Kim, Sang-We;Wu, Yi-Long;Nakagawa, Kazuhiko;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You;Atagi, Shinji;Ponce, Santiago;Shi, Xiaojin;Rukazenkov, Yuri;Haddad, Vincent;Thress, Kenneth S.;Soria, Jean-Charles |
| 2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial |
Soria, Jean-Charles;Wu, Yi-Long;Nakagawa, Kazuhiko;Kim, Sang-We;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You;Atagi, Shinji;Ponce, Santiago;Lee, Dae Ho;Liu, Yunpeng;Yoh, Kiyotaka;Zhou, Jian-Ying;Shi, Xiaojin;Webster, Alan;Jiang, Haiyi;Mok, Tony S. K. |
| 2015 |
Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup Analysis |
Soria, Jean-Charles;Kim, Sang-We;Wu, Yi-Long;Nakagawa, Kazuhiko;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You;Atagi, Shinji;Ponce, Santiago;Shi, Xiaojin;Taylor, Rosemary;Jiang, Haiyi;Thress, Kenneth;Mok, Tony |
| 2016 |
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer |
Lu, Shun;Cheng, Ying;Zhou, Cai-cun;Wang, Jie;Yang, James Chih-Hsin;Zhang, Ping-hai;Zhang, Xiao-qing;Wang, Xin;Orlando, Mauro;Wu, Yi-long |
| 2015 |
Retrospective Analysis of ctDNA EGFR Mutations in the Phase III, Randomized IMPRESS Study |
Kim, Sang-We;Wu, Yi-Long;Nakagawa, Kazuhiko;Yang, Jin-Ji;Ahn, Myung-Ju;Wang, Jie;Yang, James Chih-Hsin;Lu, You.;Atagi, Shinji;Ponce, Santiago;Soria, Jean-Charles;Mok, Tony;Shi, Xiaojin;Taylor, Rosemary;Jiang, Haiyi;Thress, Kenneth |
| Nov-2020 |
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial |
Wu, Yi-Long;Cheng, Ying;Zhou, Jianying;Lu, Shun;Zhang, Yiping;Zhao, Jun;Kim, Dong-Wan;Soo, Ross Andrew;Kim, Sang-We;Pan, Hongming;Chen, Yuh-Min;Chian, Chih-Feng;Liu, Xiaoqing;Tan, Daniel Shao Weng;Bruns, Rolf;Straub, Josef;Johne, Andreas;Scheele, Jurgen;Park, Keunchil;Yang, James Chih-Hsin |
